Troponin I Tyrosine Phosphorylation Beneficially Accelerates Diastolic Function
BACKGROUND: A healthy heart is able to modify its function and increase relaxation through post-translational modifications of myofilament proteins. While there are known examples of serine/threonine kinases directly phosphorylating myofilament proteins to modify heart function, the roles of tyrosine (Y) phosphorylation to directly modify heart function have not been demonstrated. The myofilament protein TnI (troponin I) is the inhibitory subunit of the troponin complex and is a key regulator of cardiac contraction and relaxation. We previously demonstrated that TnI-Y26 phosphorylation decreases calcium-sensitive force development and accelerates calcium dissociation, suggesting a novel role for tyrosine kinase-mediated TnI-Y26 phosphorylation to regulate cardiac relaxation. Therefore, we hypothesize that increasing TnI-Y26 phosphorylation will increase cardiac relaxation in vivo and be beneficial during pathological diastolic dysfunction.
METHODS: The signaling pathway involved in TnI-Y26 phosphorylation was predicted in silico and validated by tyrosine kinase activation and inhibition in primary adult murine cardiomyocytes. To investigate how TnI-Y26 phosphorylation affects cardiac muscle, structure, and function in vivo, we developed a novel TnI-Y26 phosphorylation-mimetic mouse that was subjected to echocardiography, pressure-volume loop hemodynamics, and myofibril mechanical studies. TnI-Y26 phosphorylation-mimetic mice were further subjected to the nephrectomy/DOCA (deoxycorticosterone acetate) model of diastolic dysfunction to investigate the effects of increased TnI-Y26 phosphorylation in disease.
RESULTS: Src tyrosine kinase is sufficient to phosphorylate TnI-Y26 in cardiomyocytes. TnI-Y26 phosphorylation accelerates in vivo relaxation without detrimental structural or systolic impairment. In a mouse model of diastolic dysfunction, TnI-Y26 phosphorylation is beneficial and protects against the development of disease.
CONCLUSIONS: We have demonstrated that tyrosine kinase phosphorylation of TnI is a novel mechanism to directly and beneficially accelerate myocardial relaxation in vivo.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:134 |
|---|---|
| Enthalten in: |
Circulation research - 134(2024), 1 vom: 05. Jan., Seite 33-45 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Salyer, Lorien G [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.01.2024 Date Revised 14.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1161/CIRCRESAHA.123.323132 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365857890 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365857890 | ||
| 003 | DE-627 | ||
| 005 | 20240314234736.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/CIRCRESAHA.123.323132 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1328.xml |
| 035 | |a (DE-627)NLM365857890 | ||
| 035 | |a (NLM)38095088 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Salyer, Lorien G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Troponin I Tyrosine Phosphorylation Beneficially Accelerates Diastolic Function |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.01.2024 | ||
| 500 | |a Date Revised 14.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: A healthy heart is able to modify its function and increase relaxation through post-translational modifications of myofilament proteins. While there are known examples of serine/threonine kinases directly phosphorylating myofilament proteins to modify heart function, the roles of tyrosine (Y) phosphorylation to directly modify heart function have not been demonstrated. The myofilament protein TnI (troponin I) is the inhibitory subunit of the troponin complex and is a key regulator of cardiac contraction and relaxation. We previously demonstrated that TnI-Y26 phosphorylation decreases calcium-sensitive force development and accelerates calcium dissociation, suggesting a novel role for tyrosine kinase-mediated TnI-Y26 phosphorylation to regulate cardiac relaxation. Therefore, we hypothesize that increasing TnI-Y26 phosphorylation will increase cardiac relaxation in vivo and be beneficial during pathological diastolic dysfunction | ||
| 520 | |a METHODS: The signaling pathway involved in TnI-Y26 phosphorylation was predicted in silico and validated by tyrosine kinase activation and inhibition in primary adult murine cardiomyocytes. To investigate how TnI-Y26 phosphorylation affects cardiac muscle, structure, and function in vivo, we developed a novel TnI-Y26 phosphorylation-mimetic mouse that was subjected to echocardiography, pressure-volume loop hemodynamics, and myofibril mechanical studies. TnI-Y26 phosphorylation-mimetic mice were further subjected to the nephrectomy/DOCA (deoxycorticosterone acetate) model of diastolic dysfunction to investigate the effects of increased TnI-Y26 phosphorylation in disease | ||
| 520 | |a RESULTS: Src tyrosine kinase is sufficient to phosphorylate TnI-Y26 in cardiomyocytes. TnI-Y26 phosphorylation accelerates in vivo relaxation without detrimental structural or systolic impairment. In a mouse model of diastolic dysfunction, TnI-Y26 phosphorylation is beneficial and protects against the development of disease | ||
| 520 | |a CONCLUSIONS: We have demonstrated that tyrosine kinase phosphorylation of TnI is a novel mechanism to directly and beneficially accelerate myocardial relaxation in vivo | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a hemodynamics | |
| 650 | 4 | |a myofibrils | |
| 650 | 4 | |a phosphorylation | |
| 650 | 4 | |a troponin I | |
| 650 | 4 | |a tyrosine | |
| 650 | 7 | |a Troponin I |2 NLM | |
| 650 | 7 | |a Calcium |2 NLM | |
| 650 | 7 | |a SY7Q814VUP |2 NLM | |
| 650 | 7 | |a Protein-Tyrosine Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Tyrosine |2 NLM | |
| 650 | 7 | |a 42HK56048U |2 NLM | |
| 700 | 1 | |a Salhi, Hussam E |e verfasserin |4 aut | |
| 700 | 1 | |a Brundage, Elizabeth A |e verfasserin |4 aut | |
| 700 | 1 | |a Shettigar, Vikram |e verfasserin |4 aut | |
| 700 | 1 | |a Sturgill, Sarah L |e verfasserin |4 aut | |
| 700 | 1 | |a Zanella, Helena |e verfasserin |4 aut | |
| 700 | 1 | |a Templeton, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Abay, Eaman |e verfasserin |4 aut | |
| 700 | 1 | |a Emmer, Kathryn M |e verfasserin |4 aut | |
| 700 | 1 | |a Lowe, Jeovanna |e verfasserin |4 aut | |
| 700 | 1 | |a Rafael-Fortney, Jill A |e verfasserin |4 aut | |
| 700 | 1 | |a Parinandi, Narasimham |e verfasserin |4 aut | |
| 700 | 1 | |a Foster, D Brian |e verfasserin |4 aut | |
| 700 | 1 | |a McKinsey, Timothy A |e verfasserin |4 aut | |
| 700 | 1 | |a Woulfe, Kathleen C |e verfasserin |4 aut | |
| 700 | 1 | |a Ziolo, Mark T |e verfasserin |4 aut | |
| 700 | 1 | |a Biesiadecki, Brandon J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Circulation research |d 1953 |g 134(2024), 1 vom: 05. Jan., Seite 33-45 |w (DE-627)NLM000001910 |x 1524-4571 |7 nnns |
| 773 | 1 | 8 | |g volume:134 |g year:2024 |g number:1 |g day:05 |g month:01 |g pages:33-45 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/CIRCRESAHA.123.323132 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 134 |j 2024 |e 1 |b 05 |c 01 |h 33-45 | ||